Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine

Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine

Abstract Background Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment across 4 attacks (CENTURION). Methods Patients were randomized 1:1:...

Full description

Saved in:
Bibliographic Details
Main Authors: C Tassorelli, S Bragg, JH Krege, EG Doty, PA Ardayfio, D Ruff, SA Dowsett, T Schwedt
Format: article
Language:EN
Published: BMC 2021
Subjects:
Lasmiditan
Clinical trial
Migraine
Safety
Adverse events
Multiple attacks
Medicine
R
Online Access:https://doaj.org/article/55ad02cbed234cf4a58c92860dd14765
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/55ad02cbed234cf4a58c92860dd14765

Similar Items